BioCentury | Aug 27, 2020
Product Development

COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus  updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme

...CEPI) Novavax Inc. VBI Vaccines Inc. Verndari Inc. AstraZeneca plc Vanderbilt University Fluidigm Corp. Tyme Technologies Inc. Infectious...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...Korfin as chief operating and chief commercial officer, a new position. She was COO at Tyme Technologies Inc....
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...serves as chairman of Poxel S.A. (Euronext:POXEL) and Artios Pharma Ltd. (Cambridge, U.K.). Cancer company Tyme Technologies Inc....
BioCentury | Jan 25, 2019
Clinical News

Tyme shares tumble after pancreatic cancer data

...were presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. Tyme Technologies Inc....
...II data Milestone: Complete Phase II (12/2019) Chris Lieu Oral SM-88, SM88, SM-88, TYME-88 American Society of Clinical Oncology ASCO Tyme Technologies Inc. Pancreatic...
BioCentury | Oct 15, 2018
Company News

Management tracks: Rhythm, Redpin

...Laboratories (NYSE:ABT) promoted EVP of Medical Devices Robert Ford to president and COO. Cancer company Tyme Technologies Inc....
BioCentury | Sep 29, 2017
Clinical News

Tyme reports Phase I data of SM-88 in metastatic cancer

...prostate cancer in 1H18 and plans to start a Phase II trial in pancreatic cancer. Tyme Technologies Inc....
...survival (PFS) and overall survival (OS) Status: Phase I data Milestone: Complete Phase II (1H18) Alicia Parker SM-88 SM88 TYME-88 Tyme Technologies Inc....
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...company also promoted Greg Anglum to SVP and CFO from chief accounting officer. Cancer play Tyme Technologies Inc....
BioCentury | Jun 23, 2017
Clinical News

Tyme reports Phase I data for TYME-88 in pancreatic cancer

...company plans to start a Phase II trial of TYME-88 to treat refractory pancreatic cancer. Tyme Technologies Inc....
...Endpoint: NA Status: Phase I data Milestone: Start Phase II (1Q18) Alex Himes SM-88 SM88 TYME-88 American Society of Clinical Oncology ASCO Tyme Technologies Inc....
BioCentury | Jun 23, 2017
Clinical News

Tyme reports Phase Ib/II data for TYME-88 in prostate cancer

...Additional data from the trial, which is enrolling about 42 patients, are expected in 2H18. Tyme Technologies Inc....
...Status: Interim Phase Ib/II data Milestone: Additional Phase Ib/II data (2H18) Alex Himes SM-88 SM88 TYME-88 American Society of Clinical Oncology ASCO Tyme Technologies Inc. Prostate-specific...
BioCentury | Mar 30, 2017
Financial News

Tyme Technologies completes private placement

...On March 22, cancer company Tyme Technologies Inc. (OTCQB:TYMI) raised $8.2 million through the sale of 3.2 million...
...warrants to purchase up to 3.2 million shares at $3. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Alicia Parker Tyme Technologies Inc....
Items per page:
1 - 10 of 11
BioCentury | Aug 27, 2020
Product Development

COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus  updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme

...CEPI) Novavax Inc. VBI Vaccines Inc. Verndari Inc. AstraZeneca plc Vanderbilt University Fluidigm Corp. Tyme Technologies Inc. Infectious...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...Korfin as chief operating and chief commercial officer, a new position. She was COO at Tyme Technologies Inc....
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...serves as chairman of Poxel S.A. (Euronext:POXEL) and Artios Pharma Ltd. (Cambridge, U.K.). Cancer company Tyme Technologies Inc....
BioCentury | Jan 25, 2019
Clinical News

Tyme shares tumble after pancreatic cancer data

...were presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. Tyme Technologies Inc....
...II data Milestone: Complete Phase II (12/2019) Chris Lieu Oral SM-88, SM88, SM-88, TYME-88 American Society of Clinical Oncology ASCO Tyme Technologies Inc. Pancreatic...
BioCentury | Oct 15, 2018
Company News

Management tracks: Rhythm, Redpin

...Laboratories (NYSE:ABT) promoted EVP of Medical Devices Robert Ford to president and COO. Cancer company Tyme Technologies Inc....
BioCentury | Sep 29, 2017
Clinical News

Tyme reports Phase I data of SM-88 in metastatic cancer

...prostate cancer in 1H18 and plans to start a Phase II trial in pancreatic cancer. Tyme Technologies Inc....
...survival (PFS) and overall survival (OS) Status: Phase I data Milestone: Complete Phase II (1H18) Alicia Parker SM-88 SM88 TYME-88 Tyme Technologies Inc....
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...company also promoted Greg Anglum to SVP and CFO from chief accounting officer. Cancer play Tyme Technologies Inc....
BioCentury | Jun 23, 2017
Clinical News

Tyme reports Phase I data for TYME-88 in pancreatic cancer

...company plans to start a Phase II trial of TYME-88 to treat refractory pancreatic cancer. Tyme Technologies Inc....
...Endpoint: NA Status: Phase I data Milestone: Start Phase II (1Q18) Alex Himes SM-88 SM88 TYME-88 American Society of Clinical Oncology ASCO Tyme Technologies Inc....
BioCentury | Jun 23, 2017
Clinical News

Tyme reports Phase Ib/II data for TYME-88 in prostate cancer

...Additional data from the trial, which is enrolling about 42 patients, are expected in 2H18. Tyme Technologies Inc....
...Status: Interim Phase Ib/II data Milestone: Additional Phase Ib/II data (2H18) Alex Himes SM-88 SM88 TYME-88 American Society of Clinical Oncology ASCO Tyme Technologies Inc. Prostate-specific...
BioCentury | Mar 30, 2017
Financial News

Tyme Technologies completes private placement

...On March 22, cancer company Tyme Technologies Inc. (OTCQB:TYMI) raised $8.2 million through the sale of 3.2 million...
...warrants to purchase up to 3.2 million shares at $3. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Alicia Parker Tyme Technologies Inc....
Items per page:
1 - 10 of 11